226 related articles for article (PubMed ID: 25243340)
41. Efficacy and safety of glycopyrrolate in patients with COPD by reversibility: pooled analysis of GEM1 and GEM2 12-week studies.
Ohar JA; Bowling A; Goodin T; Price B; Ozol-Godfrey A; Sharma S; Sanjar S
Int J Chron Obstruct Pulmon Dis; 2019; 14():461-470. PubMed ID: 30863047
[TBL] [Abstract][Full Text] [Related]
42. Dual Bronchodilation with Indacaterol Maleate/Glycopyrronium Bromide Compared with Umeclidinium Bromide/Vilanterol in Patients with Moderate-to-Severe COPD: Results from Two Randomized, Controlled, Cross-over Studies.
Kerwin E; Ferguson GT; Sanjar S; Goodin T; Yadao A; Fogel R; Maitra S; Sen B; Ayers T; Banerji D
Lung; 2017 Dec; 195(6):739-747. PubMed ID: 28993871
[TBL] [Abstract][Full Text] [Related]
43. Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies.
Martinez FJ; Lipworth BJ; Rabe KF; Collier DJ; Ferguson GT; Sethi S; Feldman GJ; O'Brien G; Jenkins M; Reisner C
Respir Res; 2020 May; 21(1):128. PubMed ID: 32450869
[TBL] [Abstract][Full Text] [Related]
44. Glycopyrronium bromide for the treatment of chronic obstructive pulmonary disease.
Riario-Sforza GG; Ridolo E; Riario-Sforza E; Incorvaia C
Expert Rev Respir Med; 2015 Feb; 9(1):23-33. PubMed ID: 25547422
[TBL] [Abstract][Full Text] [Related]
45. Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD.
Martinez FJ; Rabe KF; Ferguson GT; Fabbri LM; Rennard S; Feldman GJ; Sethi S; Spangenthal S; Gottschlich GM; Rodriguez-Roisin R; Arora S; Siler TM; Siddiqui S; Darken P; Fischer T; Maes A; Golden M; Orevillo C; Reisner C
Chest; 2017 Feb; 151(2):340-357. PubMed ID: 27916620
[TBL] [Abstract][Full Text] [Related]
46. An overview of glycopyrrolate/eFlow® CS in COPD.
Kerwin E; Ferguson GT
Expert Rev Respir Med; 2018 Jun; 12(6):447-459. PubMed ID: 29774778
[TBL] [Abstract][Full Text] [Related]
47. Randomized study of the effects of Aerochamber Plus
Fakih F; Spangenthal S; Sigal B; Darken P; Maes A; Siddiqui S; Gillen M; Reisner C; Martin UJ
Respir Med; 2018 May; 138():74-80. PubMed ID: 29724397
[TBL] [Abstract][Full Text] [Related]
48. Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized Phase III study conducted in Asia, Europe, and the USA.
Lipworth BJ; Collier DJ; Gon Y; Zhong N; Nishi K; Chen R; Arora S; Maes A; Siddiqui S; Reisner C; Martin UJ
Int J Chron Obstruct Pulmon Dis; 2018; 13():2969-2984. PubMed ID: 30310273
[TBL] [Abstract][Full Text] [Related]
49. [Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].
; ;
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Feb; 47(2):101-119. PubMed ID: 38309959
[TBL] [Abstract][Full Text] [Related]
50. Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator.
Singh D; Balaguer V; Astbury C; Wählby-Hamrén U; Jimenez E; Seoane B; Villarroel C; Lei A; Aggarwal A; Psallidas I
Respir Res; 2020 Sep; 21(Suppl 1):102. PubMed ID: 32907566
[TBL] [Abstract][Full Text] [Related]
51. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease.
Maqsood U; Ho TN; Palmer K; Eccles FJ; Munavvar M; Wang R; Crossingham I; Evans DJ
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012930. PubMed ID: 30839102
[TBL] [Abstract][Full Text] [Related]
52. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD.
Rabe KF; Martinez FJ; Ferguson GT; Wang C; Singh D; Wedzicha JA; Trivedi R; St Rose E; Ballal S; McLaren J; Darken P; Aurivillius M; Reisner C; Dorinsky P;
N Engl J Med; 2020 Jul; 383(1):35-48. PubMed ID: 32579807
[TBL] [Abstract][Full Text] [Related]
53. Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data.
D'Urzo AD; Kerwin EM; Chapman KR; Decramer M; DiGiovanni R; D'Andrea P; Hu H; Goyal P; Altman P
Int J Chron Obstruct Pulmon Dis; 2015; 10():1599-612. PubMed ID: 26316734
[TBL] [Abstract][Full Text] [Related]
54. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
[TBL] [Abstract][Full Text] [Related]
55. Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis.
Donohue JF; Kerwin E; Barnes CN; Moran EJ; Haumann B; Crater GD
BMC Pulm Med; 2020 May; 20(1):134. PubMed ID: 32393215
[TBL] [Abstract][Full Text] [Related]
56. ▾Glycopyrronium for COPD.
Drug Ther Bull; 2013 Jun; 51(6):66-8. PubMed ID: 23744364
[TBL] [Abstract][Full Text] [Related]
57. Safety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patients.
Beier J; van Noord J; Deans A; Brooks J; Maden C; Baggen S; Mehta R; Cahn A
Int J Chron Obstruct Pulmon Dis; 2012; 7():153-64. PubMed ID: 22419863
[TBL] [Abstract][Full Text] [Related]
58. Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate.
Ohar JA; Ozol-Godfrey A; Goodin T; Sanjar S
Int J Chron Obstruct Pulmon Dis; 2020; 15():995-1004. PubMed ID: 32440111
[TBL] [Abstract][Full Text] [Related]
59. Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β
Siddiqui MK; Shukla P; Jenkins M; Ouwens M; Guranlioglu D; Darken P; Biswas M
Ther Adv Respir Dis; 2019; 13():1753466619894502. PubMed ID: 31868101
[TBL] [Abstract][Full Text] [Related]
60. In Vitro Characterization of the eFlow Closed System Nebulizer with Glycopyrrolate Inhalation Solution.
Pham S; Ferguson GT; Kerwin E; Goodin T; Wheeler A; Bauer A
J Aerosol Med Pulm Drug Deliv; 2018 Jun; 31(3):162-169. PubMed ID: 29125918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
